Shikimic Acid Inducing Apoptosis on Hepatocellular Carcinoma HepG-2 Cells Through Decreasing the Ratio of Bcl-2/Bax

ZHU Kai-mei; GU Sheng-jiu; LI Mei-bo; LUO Cai-zhen; XU You-rui; GU Xiao-wen

doi:10.13422/j.cnki.syfix.2014080154

您当前的位置：

首页 >

文章列表页 >

Shikimic Acid Inducing Apoptosis on Hepatocellular Carcinoma HepG-2 Cells Through Decreasing the Ratio of Bcl-2/Bax

更新时间：2024-01-04

- Shikimic Acid Inducing Apoptosis on Hepatocellular Carcinoma HepG-2 Cells Through Decreasing the Ratio of Bcl-2/Bax
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 8, Pages: 154-158(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfix.2014080154
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
ZHU Kai-mei, GU Sheng-jiu, LI Mei-bo, et al. Shikimic Acid Inducing Apoptosis on Hepatocellular Carcinoma HepG-2 Cells Through Decreasing the Ratio of Bcl-2/Bax[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 154-158.
DOI：

ZHU Kai-mei, GU Sheng-jiu, LI Mei-bo, et al. Shikimic Acid Inducing Apoptosis on Hepatocellular Carcinoma HepG-2 Cells Through Decreasing the Ratio of Bcl-2/Bax[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 154-158. DOI： 10.13422/j.cnki.syfix.2014080154.

摘要

目的：研究八角莽草酸诱导人肝癌细胞HepG-2凋亡的作用和机制。方法：取对数生长期人肝癌HepG-2细胞，随机分为药物组和对照组，用0.125，0.5，1 g·L-1不同浓度八角莽草酸作用人肝癌HepG-2细胞，采用MTT法测定莽草酸对HepG-2细胞增殖的影响；通过流式细胞仪检测在以上浓度的莽草酸对肝癌HepG-2细胞周期的影响；通过免疫细胞化学检测凋亡相关基因B细胞淋巴瘤白血病2（Bcl-2）、Bcl-2相关X蛋白（Bax蛋白）表达的改变。结果：MTT实验结果表明，各质量浓度0.125，0.5，1 g·L-1的莽草酸对人肝癌HepG-2的生长具有显著的抑制作用（P<0.05），呈现时间依赖性和剂量依赖性；流式结果表明莽草酸将人肝癌HepG-2细胞阻滞在G1期，使细胞不能顺利地进入细胞DNA合成期S期，从而抑制了该细胞的增殖。免疫细胞化学检测凋亡相关基因Bcl-2蛋白表达明显减少、Bax表达明显增加；Bcl-2/Bax比例明显降低。结论：八角莽草酸在体外诱导人肝癌HepG-2细胞大量阻滞在G1期，进入S期细胞减少，抑制细胞增殖，其作用可能通过降低Bcl-2/Bax比例来诱导细胞凋亡而实现的。

Abstract

Objective: To investigate the effects of shikimic acid on inducing hepatocellular carcinoma HepG-2 cells apoptosis in vitro. Method: The MTT assay was used

and the hepatocellular carcinoma HepG-2 cells in logarithmic phase of growth were randomly divided into control group and treatment group treated with the concentration of 0.125

0.5

1 g·L-1 shikimic acid in hepatocellular carcinoma HepG-2 cells. The cell cycle distribution was analyzed by flow cytometry. The protein expression of B cell lymphoma/leukemia-2(Bcl-2) and Bcl-2 associated x protein(Bax) was analyzed by immunocytochemical method. Result: Shikimic acid inhibited the growth of cells significantly(P<0.05). The suppression was both in a time-and dose-dependent manner. The flow cytometry showed that shikimic acid can inhibit the proliferation by preventing cells turning into S phase from G1 phase in cell cycle

at the same time

shikimic acid down-regulated the Bcl-2 expression and up-regulated the Bax expression

the ratio of Bcl-2/Bax was evident decrease. Conclusion: Shikimic acid can inhibit proliferation hepatocellular carcinoma HepG-2 cells and induce a G1 cell cycle arrest and reduce the cell population in S phase

it may induce apoptosis through decreasing the ratio of Bcl-2/Bax.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Curcumin Induces Cycle Arrest of Colon Cancer HCT116 Cells via JAK1/STAT1/p21 Pathway

Scutellariae Barbatae Herba Extract Promotes Cycle Arrest of Nasopharyngeal Carcinoma Cells by Inhibiting STAT3/SKP2 Signaling Pathway

Mechanism of Anti-atherogenesis of Shikimic Acid from

Related Author

LIN Zidong

LIU Yunrong

SHI Denghui

DONG Wenjie

XI Zuowu

LI Tianshuo

Zilu WU

Jingbo LI

Related Institution

Second Clinical Medical College， Henan University of Chinese Medicine

Henan Province Hospital of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰